Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan.
To examine the prognostic significance of minimal residual disease (MRD) in t(8;21) acute myeloid leukemia (AML), 96 bone marrow samples from 26 Japanese patients in complete remission (CR) were analyzed regarding the RUNX1/MTG8 transcript using real-time reverse transcriptase polymerase chain reaction assay. All patients were treated with intensive chemotherapy. The median copy number of the RUNX1/MTG8 transcript, measured after each treatment course decreased over time. However, an increase in the MRD level was documented in three patients after the second consolidation, and all of them subsequently relapsed. The relapse-free survival (RFS) did not differ between the patients whose MRD levels were below or above 1,000 copies/microg after the first consolidation, with respective 2-year rates of 62 and 86% (P = 0.21). With respect to the MRD level after induction therapy, our data also failed to show any favorable effect of a lower MRD on RFS. Although these findings need to be confirmed with a larger number of patients, our data indicate that the MRD level at a given time during the early course in CR does not predict the outcome in Japanese patients.
Narimatsu
Hiroto
H
Department of Hematology and Oncology, Toyohashi Municipal Hospital, Toyohashi, Japan. narimt54@med.nagoya-u.ac.jp.|Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan. narimt54@med.nagoya-u.ac.jp.
Iino
Masaki
M
Department of Hematology, Yamanashi Prefectural Central Hospital, Kofu, Japan.
Ichihashi
Takuji
T
Department of Hematology, Okazaki City Hospital, Okazaki, Japan.
Yokozawa
Toshiya
T
Department of Hematology/Oncology, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Hayakawa
Masaya
M
Department of Hematology, Komaki City Hospital, Komaki, Japan.
Kiyoi
Hitoshi
H
Department of Infectious Diseases, Nagoya University School of Medicine, Nagoya, Japan.
Takeo
Takaaki
T
Department of Hematology, Yokkaichi Municipal Hospital, Yokkaichi, Japan.
Sawamoto
Akiyo
A
Department of Hematology and Oncology, Toyohashi Municipal Hospital, Toyohashi, Japan.
Iida
Hiroatsu
H
Department of Hematology, Meitetsu Hospital, Nagoya, Japan.
Tsuzuki
Motohiro
M
Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
Yanada
Masamitsu
M
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan.
Naoe
Tomoki
T
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan.
Suzuki
Ritsuro
R
Department of HSCT Data Management, Nagoya University School of Medicine, Nagoya, Japan.
Sugiura
Isamu
I
Department of Hematology and Oncology, Toyohashi Municipal Hospital, Toyohashi, Japan.
D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002891:Chromosomes, Human, Pair 21; D002898:Chromosomes, Human, Pair 8; D050676:Core Binding Factor Alpha 2 Subunit / Q000235:genetics*; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D018628:Gene Dosage; D006801:Humans; D015255:Idarubicin / Q000627:therapeutic use; D007564:Japan; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000188:drug therapy* / Q000235:genetics*; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D000075142:RUNX1 Translocation Partner 1 Protein; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D014157:Transcription Factors / Q000235:genetics*
D000964:Antimetabolites, Antineoplastic; D050676:Core Binding Factor Alpha 2 Subunit; D011518:Proto-Oncogene Proteins; D000075142:RUNX1 Translocation Partner 1 Protein; C493728:RUNX1 protein, human; C082222:RUNX1T1 protein, human; D014157:Transcription Factors; D003561:Cytarabine; D015255:Idarubicin; D003630:Daunorubicin